单价与三价重组MVA载体疫苗对三种脑炎性甲病毒的保护效力
研究用MVA-BN平台构建单价MVA-BN-W、MVA-BN-E、MVA-BN-V及三价MVA-BN-WEV疫苗,雌性BALB/c小鼠间隔四周免疫两剂,加强后两周以5×10³至1×10⁴空斑形成单位的WEEV、EEEV或VEEV鼻内攻击。单价疫苗组小鼠全部存活且无病征或体重下降,对照组全部死亡;三价疫苗对WEEV和VEEV攻击提供90%至100%保护,对EEEV攻击提供60%至90%保护。
要点
- 单价MVA-BN-W、MVA-BN-E、MVA-BN-V免疫小鼠对相应病毒攻击全部存活且无病征或体重下降。
- 三价MVA-BN-WEV或三价单价疫苗混合对WEEV和VEEV攻击提供90%至100%保护。
- 三价MVA-BN-WEV或三价单价疫苗混合对EEEV攻击保护为60%至90%,效力略降。
核心结论
- 单价MVA-BN-W、MVA-BN-E和MVA-BN-V分别是针对相应脑炎性甲病毒的潜在疫苗候选。
- 三种单价疫苗可混合使用,或三价MVA-BN-WEV可作为真正的多价疫苗,对WEEV和VEEV效力无显著降低,但对EEEV攻击效力略降。
研究设计与样本
- 研究用MVA-BN疫苗平台构建并生产三种单价重组疫苗MVA-BN-W、MVA-BN-E、MVA-BN-V及三价疫苗MVA-BN-WEV。
- 雌性BALB/c小鼠间隔四周免疫两剂各单价疫苗、三种单价疫苗混合MVA-BN-W+E+V或三价MVA-BN-WEV。
- 加强免疫后两周,小鼠鼻内接种5×10³至1×10⁴空斑形成单位的WEEV、EEEV或VEEV。
主要发现
- 单价疫苗免疫小鼠对相应病毒攻击全部存活,无任何病征或体重下降,对照小鼠全部死亡。
- 三价单价疫苗混合或三价MVA-BN-WEV对WEEV和VEEV攻击提供90%至100%保护。
- 三价单价疫苗混合或三价MVA-BN-WEV对EEEV攻击提供60%至90%保护。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The three encephalitic alphaviruses, western, eastern, and Venezuelan equine encephalitis viruses (WEEV, EEEV, and VEEV) are potential biothreat agents due to high infectivity through aerosol exposure, ease of production in large amounts, and relative stability in the environment. Currently, there is no licensed vaccine for human use to these three encephalitic alphaviruses, and efforts to move vaccine candidates forward into clinical trials have not been successful. In this study, the modified vaccinia Ankara-Bavarian Nordic (MVA-BN®) vaccine platform was used to construct and produce three monovalent recombinant MVA-BN-based encephalitic alphavirus vaccines, MVA-BN-W, MVA-BN-E, and MVA-BN-V. Additionally, a MVA-BN-based construct was designed to produce antigens against all three alphaviruses, the trivalent vaccine MVA-BN-WEV. The protective efficacy of these vaccines was evaluated in vivo. Female BALB/c mice were immunized with two doses of each monovalent MVA-BN-based alphavirus vaccine, a mixture of the three monovalent vaccines, MVA-BN-W + E + V, or the trivalent vaccine MVA-BN-WEV at a four-week interval. Two weeks after the booster immunization, the mice were instilled intranasally with 5 × 103 to 1 × 104 plaque forming units of WEEV, EEEV, or VEEV. All mice immunized with monovalent vaccines survived the respective virus challenge without any signs of illness or weight loss, while all the control mice died. The triple mixture of vaccines or the trivalent vaccine also provided 90 to 100% protection to the mice against WEEV and VEEV challenges, and 60% to 90% protection against EEEV challenge. These data suggest that each monovalent MVA-BN-W, MVA-BN-E, and MVA-BN-V is a potential vaccine candidate against respective encephalitic alphavirus and the three monovalent vaccines can be given in a mixture (MVA-BN-W + E + V) or the trivalent vaccine MVA-BN-WEV can serve as a true multivalent vaccine without significantly reducing efficacy against WEEV and VEEV despite slightly reduced efficacy against EEEV challenge.
引用
- Hu WG, Steigerwald R, Kalla M, et al. Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses. Vaccine. 2018. PMID: 30037666. doi:10.1016/j.vaccine.2018.06.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。